HEALTH
* Geron Corp. shares fell for the second day, after skyrocketing last week, as investors realized that the biotechnology firm’s new research on cells isn’t likely to translate into a lucrative product soon. Shares of the Menlo Park-based company fell $1.50 to close at $12.25 on Nasdaq. Geron rose 74% last week on news that the company had managed to isolate in the laboratory a human embryonic “stem cell” that can develop into any kind of human cell.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
